1	Surface sampling for SARS-CoV-2 in workplace outbreak settings in
2	the UK, 2021-22.
3	lan Nicholls <sup>1</sup> , Antony Spencer <sup>1</sup> , Yiqun Chen <sup>2</sup> , Allan Bennett <sup>1</sup> and Barry Atkinson <sup>1</sup> .
4	<sup>1</sup> Research and Evaluation, UK Health Security Agency, Porton Down, Salisbury, United Kingdom.
5	<sup>2</sup> Science Division, Health and Safety Executive, Buxton, United Kingdom.
6	
7	Correspondence: Barry Atkinson ( <u>barry.atkinson@ukhsa.gov.uk</u> )
8	Keywords: SARS-CoV-2; COVID-19; Workplace; Environmental Surface Sampling; Outbreak; Cluster;
9	Fomite; Transmission.
10	
11	Word count: Abstract = 192; Text = 3780
12	
13	ABSTRACT
14	Aims: To utilise environmental surface sampling to evaluate areas of SARS-CoV-2 contamination
15	within workplaces to identify trends and improve local COVID-control measures.
16	Methods and Results: Surface sampling was undertaken at 12 workplaces that experienced a cluster
17	of COVID-19 cases in the workforce between March 2021 and March 2022. 7.4% (61/829) of samples
18	collected were positive for SARS-CoV-2 RNA by qPCR with only 1.8% (15/829) of samples identified
19	with crossing threshold (Ct) values below 35.0. No sample returned whole genome sequence
20	inferring RNA detected was degraded.

21 Conclusions: Few workplace surface samples were positive for SARS-CoV-2 RNA and positive 22 samples typically contained low levels of nucleic acid. Although these data may infer a low 23 probability of fomite transmission or other forms of transmission within the workplace, Ct values 24 may have been lower at the time of contamination. Workplace environmental sampling identified 25 lapses in COVID-control measures within individual sites and showed trends through the pandemic. 26 Significance and Impact of the Study: Prior to this study, few published reports investigated SARS-27 CoV-2 RNA contamination within workplaces experiencing cases of COVID-19. This report provides 28 extensive data on environmental sampling identifying trends across workplaces and through the 29 pandemic.

#### 30 INTRODUCTION

31 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological cause of

32 coronavirus disease 2019 (COVID-19) which emerged in Wuhan, China in late 2019. By March 2020,

33 SARS-CoV-2 had spread globally and was declared a pandemic by the World Health Organisation

34 (WHO, 2020).

35 The UK government's initial COVID-19 control measures included limiting social interactions and 36 substantially reducing occupancy within non-essential workplaces. While these measures limited 37 potential exposure to SARS-CoV-2, the scope of workplaces deemed as essential meant millions of 38 people were required to attend their place of work with an estimated 30% of adult workers required 39 to travel to their place of work during the first UK lockdown period in May 2020 rising to 50% by May 40 2021 (ONS, 2021). These key-workers were found to have had experienced a greater exposure to, 41 and be at increased risk of COVID-19 infection (Brown, Coventry & Pepper, 2021; Topriceanu et al., 42 2021).

While the majority of workplace COVID-19 outbreaks were associated with short- and long-term care facilities including hospitals, numerous outbreaks were also reported in non-care sectors including manufacturing, retail, education and hospitality (European Centre for Disease Prevention and Control, 2020; Chen *et al.*, 2022; Hosseini *et al.*, 2022). Congregate settings where workers are frequently in close proximity were notably affected with early reports from industries such as meat processing facilities and correctional institutes (Dyal *et al.*, 2020; Saloner *et al.*, 2020); however,

49 outbreaks were reported in all workplace sectors.

A core component of understanding transmission risk within the workplace is identifying areas with SARS-CoV-2 contamination. These data not only identify higher risk areas or places where infection control measures require strengthening, but also highlight potential transmission risk areas through fomite transmission. Studies have shown that SARS-CoV-2 can remain viable on surfaces for numerous days after deposition (Riddell *et al.*, 2020; van Doremalen *et al.*, 2020; Paton *et al.*, 2021;

55	Sun <i>et al.</i> , 2022) while the nucleic acid can be detected for numerous weeks (Liu <i>et al.</i> , 2021a,
56	2021b; Paton et al., 2021; Coil et al., 2022). The persistence of SARS-CoV-2 viral particles and nucleic
57	acid on surfaces therefore allows for sampling of workplaces to determine potential risk areas and
58	transmission risk among workers.
59	As part of the COVID-19 Outbreak investigation to Understand Transmission study (COVID-OUT)
60	study, environmental surface sampling was conducted at workplaces reporting cases of COVID-19
61	within their workforce to establish areas of contamination within workplaces, potential routes of
62	transmission, and to learn lessons from workplace outbreaks which can be incorporated into wider
63	guidance. The data generated could also provide insight into whether COVID-19 cases affecting
64	businesses are predominately workplace-related (resulting from factors within the work
65	environment) or workforce-related resulting from interactions outside of a place of work and
66	beyond the control of the employer.

## 68 METHODS

## 69 Recruitment to the COVID-OUT study

70 Workplaces in the UK are required to report potential outbreaks to the Health and Safety Executive 71 (HSE) and United Kingdom Health Security Agency (UKHSA). Identification and recruitment of 72 workplaces experiencing cases of COVID-19 in their workforce was conducted using these databases 73 as part of the wider COVID-OUT study (Chen et al., 2021). To be eligible for inclusion in this study, a 74 workplace was required to have an attack rate of ≥5% at the time of notification in a workforce of 75 ≥100 workers as well as qualifying as one of the following facilities: food processing plants, general 76 manufacturing facilities, packaging and distribution centres, or large office buildings. Smaller 77 workplaces (<100 workers) were approached if >5 workers were infected at the time of notification

78 with projected increases. Workplaces meeting the criteria for study inclusion were approached for 79 approval to participate in the study including the option for environmental surface sampling. 80 In addition, two control sites were sampled at separate times during the course of the study to 81 represent the background levels of surface contamination which could be expected from a 82 workplace which was not experiencing, and had not recently experienced, an elevated level of 83

COVID-19 infections.

#### 84 Surface sampling

85 Environmental surface sampling was performed as soon as practicable after a participation

86 agreement was in place. An on-site reconnaissance of the overall work environment was carried out

87 to identify priority areas for sampling such as door handles, toilets, canteens, high-occupancy

88 workstations/desks and locker rooms. Areas occupied by workers who had been recently diagnosed

89 with COVID-19 infection were also targeted.

90 Surface sampling was carried out using either Blue Stick Sponge Swabs (Technical Service

Consultants, TS/15-SH) or Blue Sponge Swabs (Technical Service Consultants, TS/15-B) for flat 91

92 surfaces, and Universal Transport Medium (UTM) Swabs (Copan, 366C) for smaller or more detailed

93 surface areas such as door handles. Where possible, samples were collected from an approximate

94 10cm x 10cm area to allow for estimation of contamination should heavily contaminated

95 environments be identified. For each sample, an estimate of the area sampled was recorded in

96 addition to the type of environment sampled and whether the sample was from a 'high-touch' area

97 (likely to be contacted at least twice per working day by at least two separate individuals).

98 Sample team members wore an IRII surgical mask and two pairs of nitrile gloves to prevent potential 99 (cross-)contamination of samples in addition to any other personal protective equipment required to 100 operate in the specific work environment e.g., ear defenders. Collected samples were packaged into

a UN3373 rated container for transport back to the laboratory and stored at 4°C until subsequent
 processing (16-60hrs).

# 103 Sample Analysis

Samples were processed within a class II microbiological safety cabinet. Sponge samples were manually massaged by hand for approximately 30 seconds in their sample bags to homogenise the sample and release absorbed buffer which was then removed from the bag using a serological pipette and stored in a 2mL Sarstedt tube. UTM swabs were pressed against the inside edge of the collection tube in a rolling motion to release any retained UTM which was then removed by pipette and stored in a 2mL Sarstedt tube. When lysis and RNA purification was not carried out immediately, samples were placed into storage in a -80°C freezer.

111 SARS-CoV-2 RNA was extracted and purified from samples using QIAamp Viral RNA Mini Kit (Qiagen, 112 52906) following the manufacturer's centrifuge protocol. Quantitative PCR (qPCR) was carried out 113 using the Viasure SARS-CoV-2 detection kit (CerTest, VS-NC02) following manufacturer's instructions. 114 The targets for this assay were the SARS-CoV-2 nucleocapsid gene (N) and polyprotein open reading 115 frame 1a and 1b (ORF1ab). Assay analysis was performed on a QuantStudio 5 thermocycler (Applied 116 Biosystems) against an in-house N gene standard curve to determine approximate genome copy 117 number in positive samples. The cycling conditions were as follows: one reverse transcription cycle 118 of 45°C for 15 mins followed by denaturation at 95°C for 2 mins, then 45 cycles of 95°C for 10 secs 119 and 60°C for 50 secs with quantification of fluorescence performed at the end of 60°C step. All 120 samples were tested in duplicate against both targets. Samples were deemed positive when both 121 duplicate tests returned a valid crossing threshold (Ct) value for either target. If only a single 122 replicate returned a valid Ct value, repeat analysis was performed; if the same result was returned 123 the sample was referred to as 'suspected positive' unless two valid Ct values were recorded for the 124 other target. Samples were deemed negative when no Ct value was returned for either replicate in 125 both targets. Invalid Ct values were those above Ct 38.0 which is the upper limit described by the kit

- 126 manufacturer; samples with Ct values above 38.0 were deemed as 'technical negatives' and
- 127 considered as negatives.

## 128 Additional analysis

- 129 Samples returning Ct values of ≤35.0 cycles were subjected whole genome sequencing using the
- 130 ARTIC Network protocol (Quick, 2020, using v4.1 primers) to elucidate detailed genetic composition
- 131 of the contaminating virus. Any sample returning complete viral genome would be eligible for viral
- 132 isolation to demonstrate the presence of infectious virus.

133

#### 134 **RESULTS**

#### 135 Workplace recruitment

136 Environmental surface sampling for SARS-CoV-2 contamination was performed at 12 workplaces 137 (Sites 001-005, 007-010, 012-013 and 020) and two control sites (C1 and C2) between March 2021 138 and March 2022 (Table 1). The recruited sites spanned numerous essential workplace sectors 139 including manufacturing (four sites), food (four sites), office-based workplaces (two sites), 140 distribution (one site) and critical infrastructure (one site); the two control sites were both within 141 the critical infrastructure sector. Cases of COVID-19 among the workforce of recruited sites had 142 either ceased or were declining in all cases at the time of environmental sampling; however, cases of 143 COVID-19 were still being reported among the workforce at sites 002, 003, 005 and 008 when 144 sampling was performed. Sites 001, 002, 003, 004, 005, 010, 012 and 013 met the inclusion criteria 145 of  $\geq$ 100 employees and  $\geq$ 5% attack rate at the time of the outbreak report; sites 008, 009 and 020 146 had  $\leq 100$  staff but  $\geq 5$  confirmed cases at the time of the outbreak report with projected increases. 147 Site 005 did not achieve a  $\geq$ 5% attack rate in its workforce of more than 1000 employees; however, 148 this site recorded a large number of cases in a short period of time and was recruited based on

projected increases. The two control sites both had ≥300 staff but without indication of a potential
outbreak within the workplace; however, both sites had sporadic cases at the time of sampling.
The complex recruitment process resulted in several sites being sampled at least two weeks from
the last reported case in the work environment linked to the reported outbreak (sites 004, 007, 009,
012 and site 013).

154

155 Detection of SARS-CoV-2 RNA across workplaces

A total of 829 samples were collected from the 12 recruited workplaces (average = 63.7 samples per site). 723 samples (87.2%) were negative for SARS-CoV-2 RNA; 61 samples (7.4%) were identified as positive for SARS-CoV-2 RNA and 45 samples (5.4%) identified as suspected positive (Table 2). Only 15/829 (1.8%) of samples collected across the 12 workplaces returned Ct values of  $\leq$ 35.0. Estimated genome copy numbers for samples with Ct values of  $\leq$ 35.0 ranged from 6.8x10<sup>2</sup> to 6.6x10<sup>3</sup> genomic copies/cm<sup>2</sup>.

162 A total of 136 samples were collected from two control sites (average = 68 per site) that were not

163 currently experiencing an outbreak of SARS-CoV-2. 131 samples (96.4%) were negative for SARS-

164 CoV-2 RNA and one sample (0.7%) was identified as positive with another four samples (2.9%)

identified as suspected positive (Table 3). The lowest Ct value identified at the control sites was 36.9;

estimated genome copy numbers for the five samples returning a Ct value ranged from 1.1x10<sup>2</sup> to

167  $1.2 \times 10^3$  genomic copies/cm<sup>2</sup>.

As shown in Figure 1, samples collected at the first three workplaces (sites 001-003; March – early May 2021) had a high proportion of positive samples (12.1-38.9%). In contrast, from late May 2021 onwards (Sites 004-020), only one site was identified with >3% of positive samples. A similar trend was seen with samples identified as 'suspected positive' with 8.3-18.4% of samples collected at the first five sites (March-June 2021) whereas no site was identified with more than 2.4% of samples as

- suspected positive after June 2021. The outlier in terms of positive samples was the first of two visits
- to Site 008 (September 2021) where 16.7% of samples were positive; this investigation was
- 175 conducted at the start of a rise in community cases associated with the Delta variant in a workplace
- 176 with a 55% attack rate among the workforce (Atkinson *et al.*, 2022).
- 177 Only 15/829 (1.8%) of samples collected at recruited workplaces returned Ct values of ≤35.0. These
- 178 15 samples were identified at four distinct sites: 001 (n=2), 003 (n=7), 005 (n=1) and 008 (n=5).
- 179 No positive or suspected positive samples were found at four of the 12 workplaces sampled (007,
- 180 010, 012 and 013), and in the final six months of the study (sites 009-010, 012-013 and 020) no
- 181 positive samples (0/330; 0.0%) and only two suspected positive samples (2/330; 0.6%) were
- 182 identified.

## 183 Detection of SARS-CoV-2 RNA within workplaces

- 184 SARS-CoV-2 RNA was detected in nearly all types of workplace environment (Figure 2). The highest
- rate of confirmed positivity was observed in locker rooms (13.4%) followed by general work areas
- 186 (8.8%), ventilation (6.9%), canteens (4.2%) and toilets (2.0%). No positive samples were identified in
- 187 corridors or from samples collected outside.
- 188 The level of suspected positive samples was broadly similar for work areas, canteens, locker rooms
- and toilets (6.6-9.0%). The level of suspected positives was higher for ventilation (13.8%) and for
- 190 outside samples (25.0%); however, only four samples were collected from outside environments. No
- 191 suspected positive samples were identified from corridors.
- 192 Samples with qPCR Ct values  $\leq$  35.0 cycles were only identified in locker rooms (4.5%), toilets (2.0%),
- 193 work areas (1.8%) and canteens (1.2%).
- 194 524 of the 829 samples collected from recruited workplaces were classified as being from 'high-
- 195 touch' locations (Figure 3). Levels of confirmed positivity were broadly similar for high-touch
- samples versus all samples from that environment for work areas (7.5% vs 8.8%), canteens (4.5% vs

197 4.2%) and toilets (2.9% vs 2.0%); however, there was a small reduction in the positivity rate for high-198 touch samples in locker rooms (9.1% vs 13.4%) and no positive samples were identified from high-199 touch ventilation samples (0.0% vs 6.9%). As there were no positive samples identified in any 200 corridor or outside sample, none of the high-touch samples in these groups were positive. 201 A similar trend was seen in suspected positive samples with comparable levels for high-touch 202 samples versus all samples in that environment for outside samples (25.0% vs 25.0%), work areas 203 (7.2% vs 7.0%), and canteens (6.4% vs 6.6%). There was an apparent reduction in suspected 204 positivity rate in high-touch samples for toilets (5.9% vs 7.8%), locker rooms (4.5% vs 9.0%) and 205 ventilation samples (0.0% vs 13.8%). As there were no suspected positive samples identified in any 206 corridor sample, none of the high-touch samples in this group was suspected positive. 207 For samples with a Ct value  $\leq$  35.0, levels were marginally higher for high-touch samples versus all 208 samples in that environment for toilets areas (2.9% vs 2.0%), work areas (2.1% vs 1.8%) and 209 canteens (1.3% vs 1.2%). No Ct values ≤35.0 were identified in high-touch locker room samples 210 compared to 4.5% of all samples with Ct values ≤35.0 within this environment. As there were no 211 samples with Ct values ≤35.0 identified in any ventilation, corridor, or outside sample, none of the 212 high-touch samples in these groups had Ct values ≤35.0.

213

# 214 Whole genome sequence analysis

The 15 samples returning N gene Ct values of ≤35.0 (32.7 to 35.0) were subjected to whole genome sequence analysis. No sample yielded complete genome data and only two samples generated any contiguous sequence once quality control standards were applied. Approximately 55% of the SARS-CoV-2 genome was recovered from a sample collected from a window handle at Site 008; however, the longest contiguous sequence was ~1300 bases implying the nucleic acid was sheared potentially through degradation in the environment from the contamination event until the point of sampling

221 (>9 days). The other sample to return sequence data was collected in a toilet at Site 005; however,

222 <500 bases were called representing just over 2% of the viral genome.

223

# 224 DISCUSSION

225	Workplace outbreaks of COVID-19 were common across multiple workplace sectors during the
226	pandemic despite significant efforts including government guidance and frameworks aimed at
227	reducing the spread of infection. While government guidance and workplace COVID-control
228	measures were aimed at reducing transmission of COVID-19 within the workplace, the effect of non-
229	workplace transmission among the workforce is difficult to elucidate. Workforce mixing can occur in
230	non-workplace locations such as social locations, transport to and from the workplace, and within
231	the home. This study aimed to investigate areas of surface contamination within workplaces which
232	experienced a recent COVID-19 outbreak and use this data to inform improvements to control
233	measures which can mitigate reoccurrence.

234 Between March 2021 and March 2022, 829 surface samples were collected from 12 workplaces that 235 recently experienced an outbreak of COVID-19 among their workforces. These workplaces were 236 located across the United Kingdom spanning multiple business sectors and encompassing a variety 237 of workforce sizes. Across all sites visited, only 7.4% of samples collected were identified as positive 238 by qPCR analysis with a further 5.4% identified as 'suspected positive' likely indicating SARS-CoV-2 239 genetic material close to the limit of detection for the assay. The remaining 87.2% of samples collected were negative. Estimates of genome copies per cm<sup>2</sup> of SARS-CoV-2 RNA positive surface 240 241 samples were calculated using a standard curve with no sample collected exceeding 6.6x10<sup>3</sup> genomic 242 copies/cm<sup>2</sup>. While finding limited amounts of SARS-CoV-2 nucleic acid at sites reporting a COVID-19 243 cases may seem counter-intuitive, low levels of contamination were reported in similar studies 244 including the in areas recently occupied by symptomatic workers (Gholipour et al., 2020; Marshall et 245 al., 2020; Mouchtouri et al., 2020; Cherrie et al., 2021; Marcenac et al., 2021; de Rooij et al., 2023)

and in some clinical settings occupied by infected patients (Ryu *et al.*, 2020; Goel *et al.*, 2022;

Warren *et al.*, 2022). Two control sites were also sampled as part of this study; both positive and suspected positive samples were identified at these sites albeit at lower levels than in recruited sites. These findings are likely due to both control sites reporting COVID-19 cases near the time of sampling; however, the levels were below the inclusion criteria for the study.

251 Samples with Ct values less than 35.0 were detected only at four sites (sites 001, 003, 005, and 008) 252 and in no samples collected after September 2021. The five samples with Ct values of ≤35.0 at Site 253 008 were identified after the apparent decrease in environmental surface sampling positivity rates 254 seen in late May 2021 implying that a decrease in the proportion of samples identified as SARS-CoV-255 2 positive does not necessarily correlate with level of contamination that can be observed when 256 positive samples are identified. The reduction in sample positivity levels after May 2021 and the 257 absence of positive samples after September 2021 is likely due to a combination of factors. It is 258 possible that one significant factor was the impact from the COVID-19 vaccine rollout starting in 259 December 2020 with more than 34 million priming vaccine doses administered by May 2021 260 (GOV.UK, 2022). As vaccines were made available using a tiering system based on age and at-risk 261 status, most working age individuals would likely have received at least one dose by summer 2021 262 when environmental sampling positivity rates declined. Some studies suggest that vaccine status has 263 no effect on viral titre and shedding by infected individuals (Boucau et al., 2022; Riemersma et al., 264 2022); however, other studies suggest that infectious viral titre and/or shedding duration is reduced 265 in vaccinated individuals (Ke et al., 2022; Plante et al., 2022; Puhach et al., 2022; Tian et al., 2022). 266 Additionally, a ferret model study found a significant reduction in viral titre in both nasal wash and 267 oral swabs amongst animals vaccinated with only a primer dose of Astra-Zeneca vaccine 7 days after 268 viral challenge (Marsh et al., 2021). A reduction in viral titre and shortened shedding therefore may 269 reduce environmental contamination from vaccinated cases.

Samples producing Ct values of ≤35.0 were submitted for whole genome sequencing; however, only
two yielded sequence data and neither returned more than 55% of the genome. The inability to
recover full genome sequence infers degradation of genomic material between the original
deposition and environmental sampling. While this suggests the lack of infection-competent
material in the samples collected, these contamination events may have harboured infectious
material prior to sampling and does not conclusively rule out the potential for fomite transmission in
the workplace.

277 Comparison of the types of surfaces sampled showed positives and suspected positives from all 278 major surface types. Samples from locker rooms were the most common area to return a qPCR 279 positive (13.8% of locker room samples) and a Ct value  $\leq$  35.0 (4.5% of locker room samples) 280 indicative of higher amount of nucleic acid; this may reflect an increased risk due to being a small 281 congregative area but could also reflect an oversight of local COVID control measures and cleaning 282 regimens as most locker rooms did not have the same cleaning standards seen elsewhere in the 283 workplaces. Toilets, canteens and general work areas had a comparably lower rate of positivity, and 284 high-touch surfaces had comparable, or lower, rates of positivity in all environments; it is likely that 285 enhanced cleaning regimens in high-use work areas contribute to these findings. 286 Data generated as part of this study provided site-specific information that was used to improve 287 local COVID-19 control measures. A report of surface contamination and interpretation was 288 provided to each site within five working days of sampling allowing for alterations to cleaning and 289 infection control regimes locally if required. For example, sampling of Site 008 identified a Ct 33.6 290 sample from a window handle; after consultation, it was confirmed that window handles had been 291 omitted from their enhanced cleaning procedures. Additionally, surface sampling showed an area 292 with a high positivity rate; this area was operated by a contractor who had not updated the infection

293 control policies in line with new guidance. These findings highlight the benefit that rapid

294 environmental sampling can offer to workplaces experiencing outbreaks.

295 Although the data presented provide substantial information regarding workplace contamination, 296 there are several limitations that require consideration. The time from reporting a potential 297 workplace outbreak until environmental sampling could be performed was frequently more than 14 298 days due to site approval requirements of the study meaning some nucleic acid degradation may 299 have occurred which would affect levels detected by qPCR. This delay also meant that air sampling 300 of workplaces was not considered as part of the study. Additionally, while COVID-OUT was a 301 research study, the lead organisations (UKHSA and HSE) have regulatory roles which may not only 302 have resulted in a lower rate of participation in the study but could also have resulted in 303 participating sites modifying the environment before the sampling team arrived as they may view 304 the sampling visit as an official audit. Even if all sites sampled were genuine representations of the 305 work environments at the time of cases being reported, the breadth of business and worker 306 functions combined with epidemiological differences in local infection rates, the circulating SARS-307 CoV-2 variant, and increasing vaccination rates through the study period limits the conclusions that 308 can be drawn when comparing individual sites to one another or on trends. Finally, assessment of 309 contamination was made using qPCR Ct values; while this provide a semi-quantitative assessment, it 310 does not distinguish between viable and degraded viral material, and variation can occur between 311 reactions which has greater impact on accuracy near the limit of detection which was frequently the 312 level of contamination observed in this study.

The environmental sampling carried out in this study provides data on the occurrence and the level of SARS-CoV-2 contamination seen in a variety of workplaces experiencing COVID-19 cases within their workforce throughout the pandemic. From a site-specific perspective, the data generated provided insight for where COVID control measures, workforce practices and regular cleaning may have been insufficient or may have lapsed; collectively, these results highlight common themes that may contribute to overall transmission either directly or as an indication of where transmission risks are the highest.

## 321 ACKOWLEDGMENTS

- 322 The authors wish to acknowledge the contributions of the UKHSA Genomics team for sequencing
- 323 samples and from the COVID-OUT workplace recruitment team (Chris Keen, Gillian Frost, Joan Cook,
- 324 Gary Dobbin, Derek Morgan, Vince Sandys, Matthew Coldwell, Andrew Simpson, Adam Clarke, Alice
- 325 Graham, Hannah Higgins, Christina Atchison and Helen Collins) for assistance with recruitment and
- 326 completing the wider study.

## 327 CONFLICTS OF INTEREST

328 No conflict of interest declared.

#### 329 DISCLOSURE STATEMENT

- 330 The contents of this paper, including any opinions and/or conclusions expressed, are those of the
- 331 authors alone and do not necessarily reflect Health and Safety Executive or UK Health Security
- 332 Agency policy.

## 333 FUNDING STATEMENT

- 334 This work was supported by funding from the PROTECT COVID-19 National Core Study on
- 335 Transmission and Environment, managed by the Health and Safety Executive on behalf of HM
- 336 Government.

# 337 ETHICAL APPROVAL

- 338 The COVID-OUT study has been approved by the NHS North East Research Ethics Committee
- 339 (Reference 20/NE/0282).

340

#### 341 **REFERENCES**

Atkinson, B., Veldhoven, K. van, Nicholls, I., Coldwell, M., Clarke, A., Frost, G., Atchison, C.J., Raja,
 A.I., Bennett, A.M., Morgan, D., Pearce, N., Fletcher, T., Brickley, E.B. and Chen, Y. (2022) An

outbreak of SARS-CoV-2 in a public-facing office in England, 2021. *medRxiv*.
2022.01.31.22269194.

- Boucau, J., Marino, C., Regan, J., Uddin, R., Choudhary, M.C., Flynn, J.P., Chen, G., Stuckwisch, A.M.,
  Mathews, J., Liew, M.Y., Singh, A., Lipiner, T., Kittilson, A., Melberg, M., Li, Y., Gilbert, R.F.,
  Reynolds, Z., Iyer, S.L., Chamberlin, G.C., Vyas, T.D., Goldberg, M.B., Vyas, J.M., Li, J.Z., Lemieux,
  J.E., Siedner, M.J. and Barczak, A.K. (2022) Duration of Shedding of Culturable Virus in SARS-
- 350 CoV-2 Omicron (BA.1) Infection. *N Engl J Med.* **387**, 275–277.
- Brown, R., Coventry, L. and Pepper, G. (2021) Information seeking, personal experiences, and their
   association with COVID-19 risk perceptions: demographic and occupational inequalities. *J Risk Res.* 24, 506–520.
- Chen, Y., Aldridge, T., Ferraro, C. and Khaw, F.-M. (2022) COVID-19 outbreak rates and infection
  attack rates associated with the workplace: a descriptive epidemiological study. *BMJ Open.* 12, e055643.
- Chen, Y., Atchison, C., Atkinson, B., Barber, C., Bennett, A., Brickley, E., Cooke, J., Dabrera, G.,
  Fishwick, D., Fletcher, T., Graham, A., Higgins, H., Keen, C., Morgan, D., Noakes, C., Pearce, N.,
  Raja, A., Sandys, V., Stocks, J., van Tongeren, M., van Veldhoven, K., Verma, A. and Curran, A.
  (2021) The COVID-OUT study protocol: COVID-19 outbreak investigation to understand
  workplace SARS-CoV-2 transmission in the United Kingdom. *Wellcome Open Res.* 6, 201.
- 362 Cherrie, J.W., Cherrie, M.P.C., Smith, A., Holmes, D., Semple, S., Steinle, S., Macdonald, E., Moore, G.
  363 and Loh, M. (2021) Contamination of Air and Surfaces in Workplaces with SARS-CoV-2 Virus: A
  364 Systematic Review. Ann Work Expo Heal. 65, 879–892.
- Coil, D.A., Pechacek, R., Kaze, M., Zuniga-Montanez, R., Guerrero, R.G., Eisen, J.A., Shapiro, K. and
   Bischel, H.N. (2022) SARS-CoV-2 RNA Is Readily Detectable at Least 8 Months after Shedding in
   an Isolation Facility. *mSphere*.
- van Doremalen, N., Bushmaker, T., Morris, D.H., Holbrook, M.G., Gamble, A., Williamson, B.N.,
  Tamin, A., Harcourt, J.L., Thornburg, N.J., Gerber, S.I., Lloyd-Smith, J.O., de Wit, E. and Munster,
  V.J. (2020) Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *N Engl J Med.* 382, 1564–1567.
- 372 Dyal, J.W., Grant, M.P., Broadwater, K., Bjork, A., Waltenburg, M.A., Gibbins, J.D., Hale, C., Silver, M., 373 Fischer, M., Steinberg, J., Basler, C.A., Jacobs, J.R., Kennedy, E.D., Tomasi, S., Trout, D., Hornsby-374 Myers, J., Oussayef, N.L., Delaney, L.J., Patel, K., Shetty, V., Kline, K.E., Schroeder, B., Herlihy, 375 R.K., House, J., Jervis, R., Clayton, J.L., Ortbahn, D., Austin, C., Berl, E., Moore, Z., Buss, B.F., 376 Stover, D., Westergaard, R., Pray, I., DeBolt, M., Person, A., Gabel, J., Kittle, T.S., Hendren, P., 377 Rhea, C., Holsinger, C., Dunn, J., Turabelidze, G., Ahmed, F.S., DeFijter, S., Pedati, C.S., Rattay, 378 K., Smith, E.E., Luna-Pinto, C., Cooley, L.A., Saydah, S., Preacely, N.D., Maddox, R.A., Lundeen, 379 E., Goodwin, B., Karpathy, S.E., Griffing, S., Jenkins, M.M., Lowry, G., Schwarz, R.D., Yoder, J., 380 Peacock, G., Walke, H.T., Rose, D.A. and Honein, M.A. (2020) COVID-19 Among Workers in 381 Meat and Poultry Processing Facilities — 19 States, April 2020. MMWR Morb Mortal Wkly Rep. 382 69.
- European Centre for Disease Prevention and Control (2020) COVID-19 clusters and outbreaks in
   occupational settings in the EU/EEA and the UK. *Tech Rep.* 1–17.
- Gholipour, S., Nikaeen, M., Mohammadi Manesh, R., Aboutalebian, S., Shamsizadeh, Z., Nasri, E. and
   Mirhendi, H. (2020) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
   Contamination of High-touch Surfaces in Field Settings. *Biomed Environ Sci.* 33, 925–929.
- 388 Goel, V., Gupta, S., Gupta, V. and Sahni, A.K. (2022) Environmental surface sampling for SARS-CoV-2

- around hospitalized patients with COVID-19 in a tertiary care hospital. *Asian J Med Sci.* 13, 27–
   31.
- 391 GOV.UK (2022) Coronavirus (Covid-19) in the UK [WWW Document]. URL
   392 https://coronavirus.data.gov.uk.
- Hosseini, P., Mueller, W., Rhodes, S., Pembrey, L., van Tongeren, M., Pearce, N., Loh, M. and
  Fletcher, T. (2022) Transmission and Control of SARS-CoV-2 in the Food Production Sector: A
  Rapid Narrative Review of the Literature. *Int J Environ Res Public Health*. 19, 12104.
- 396 Ke, R., Martinez, P.P., Smith, R.L., Gibson, L.L., Achenbach, C.J., McFall, S., Qi, C., Jacob, J., Dembele, 397 E., Bundy, C., Simons, L.M., Ozer, E.A., Hultquist, J.F., Lorenzo-Redondo, R., Opdycke, A.K., 398 Hawkins, C., Murphy, R.L., Mirza, A., Conte, M., Gallagher, N., Luo, C.H., Jarrett, J., Conte, A., 399 Zhou, R., Farjo, M., Rendon, G., Fields, C.J., Wang, L., Fredrickson, R., Baughman, M.E., Chiu, 400 K.K., Choi, H., Scardina, K.R., Owens, A.N., Broach, J., Barton, B., Lazar, P., Robinson, M.L., 401 Mostafa, H.H., Manabe, Y.C., Pekosz, A., McManus, D.D. and Brooke, C.B. (2022) Longitudinal 402 Analysis of SARS-CoV-2 Vaccine Breakthrough Infections Reveals Limited Infectious Virus 403 Shedding and Restricted Tissue Distribution. Open Forum Infect Dis. 9, 1-7.
- Liu, H., Fei, C., Chen, Y., Luo, S., Yang, T., Yang, L., Liu, J., Ji, X., Wu, W. and Song, J. (2021a)
  Investigating SARS-CoV-2 persistent contamination in different indoor environments. *Environ Res.* 202, 111763.
- Liu, J., Liu, J., He, Z., Yang, Z., Yuan, J., Wu, H., Zhu, P., Fu, X., Lin, Y., Zhang, Y., Zhao, Z., He, S. and
  Ma, X. (2021b) Duration of SARS-CoV-2 positive in quarantine room environments: A
  perspective analysis. *Int J Infect Dis.* **105**, 68–74.
- Marcenac, P., Park, G.W., Duca, L.M., Lewis, N.M., Dietrich, E.A., Barclay, L., Tamin, A., Harcourt, J.L.,
  Thornburg, N.J., Rispens, J., Matanock, A., Kiphibane, T., Christensen, K., Pawloski, L.C., Fry,
  A.M., Hall, A.J., Tate, J.E., Vinjé, J., Kirking, H.L. and Pevzner, E. (2021) Detection of SARS-CoV-2
  on Surfaces in Households of Persons with COVID-19. *Int J Environ Res Public Health*. 18, 8184.
- Marsh, G.A., McAuley, A.J., Au, G.G., Riddell, S., Layton, D., Singanallur, N.B., Layton, R., Payne, J.,
  Durr, P.A., Bender, H., Barr, J.A., Bingham, J., Boyd, V., Brown, S., Bruce, M.P., Burkett, K.,
  Eastwood, T., Edwards, S., Gough, T., Halpin, K., Harper, J., Holmes, C., Horman, W.S.J., van
  Vuren, P.J., Lowther, S., Maynard, K., McAuley, K.D., Neave, M.J., Poole, T., Rootes, C., Rowe,
  B., Soldani, E., Stevens, V., Stewart, C.R., Suen, W.W., Tachedjian, M., Todd, S., Trinidad, L.,
  Walter, D., Watson, N., Drew, T.W., Gilbert, S.C., Lambe, T. and Vasan, S.S. (2021) ChAdOx1
- 420 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets. *npj* 421 *Vaccines*. 6, 1–8.
- Marshall, D.L., Bois, F., Jensen, S.K.S., Linde, S.A., Higby, R., Rémy-McCort, Y., Murray, S., Dieckelman,
  B., Sudradjat, F. and Martin, G.G. (2020) Sentinel Coronavirus environmental monitoring can
  contribute to detecting asymptomatic SARS-CoV-2 virus spreaders and can verify effectiveness
  of workplace COVID-19 controls. *Microb Risk Anal.* 16, 100137.
- Mouchtouri, V.A., Koureas, M., Kyritsi, M., Vontas, A., Kourentis, L., Sapounas, S., Rigakos, G.,
  Petinaki, E., Tsiodras, S. and Hadjichristodoulou, C. (2020) Environmental contamination of
  SARS-CoV-2 on surfaces, air-conditioner and ventilation systems. *Int J Hyg Environ Health*. 230,
  113599.
- ONS (2021) Business and individual attitudes towards the future of homeworking. Analysis of the
   effects of the coronavirus (COVID-19) pandemic on office working and of business and
   individual attitudes to future working practices. [WWW Document]. URL
- $434 \hspace{1.5cm} eetypes/articles/business and individual attitudes towards the future of homeworking uk/a priltoma$

- 435 y2021.
- Paton, S., Spencer, A., Garratt, I., Thompson, K.-A., Dinesh, I., Aranega-Bou, P., Stevenson, D., Clark,
  S., Dunning, J., Bennett, A. and Pottage, T. (2021) Persistence of Severe Acute Respiratory
  Syndrome Coronavirus 2 (SARS-CoV-2) Virus and Viral RNA in Relation to Surface Type and
  Contamination Concentration. *Appl Environ Microbiol.* 87.
- Plante, J.A., Machado, R.R.G., Mitchell, B.M., Shinde, D.P., Walker, J., Scharton, D., McConnell, A.,
  Saada, N., Liu, J., Khan, B., Campos, R.K., Johnson, B.A., Menachery, V.D., Levine, C.B., Ren, P.,
  McLellan, S.L.F., Plante, K.S. and Weaver, S.C. (2022) Vaccination Decreases the Infectious Viral
  Load of Delta Variant SARS-CoV-2 in Asymptomatic Patients. *Viruses.* 14.
- Puhach, O., Adea, K., Hulo, N., Sattonnet, P., Genecand, C., Iten, A., Jacquérioz, F., Kaiser, L., Vetter,
  P., Eckerle, I. and Meyer, B. (2022) Infectious viral load in unvaccinated and vaccinated
  individuals infected with ancestral, Delta or Omicron SARS-CoV-2. *Nat Med.* 28, 1491–1500.
- 447 Quick, J. (2020) nCoV-2019 sequencing protocol v3 (LoCost) V.3. protocols.io.
- Riddell, S., Goldie, S., Hill, A., Eagles, D. and Drew, T.W. (2020) The effect of temperature on
  persistence of SARS-CoV-2 on common surfaces. *Virol J.* 17, 1–7.
- Riemersma, K.K., Haddock, L.A., Wilson, N.A., Minor, N., Eickhoff, J., Grogan, B.E., Kita-Yarbro, A.,
  Halfmann, P.J., Segaloff, H.E., Kocharian, A., Florek, K.R., Westergaard, R., Bateman, A.,
  Jeppson, G.E., Kawaoka, Y., O'Connor, D.H., Friedrich, T.C. and Grande, K.M. (2022) Shedding of
  infectious SARS-CoV-2 despite vaccination. *PLoS Pathog.* 18, 1–13.
- de Rooij, M.M.T., Sikkema, R.S., Bouwknegt, M., de Geus, Y., Stanoeva, K.R., Nieuwenweg, S., van
  Dam, A.S.G., Raben, C., Dohmen, W., Heederik, D., Reusken, C., Meijer, A., Koopmans, M.P.G.,
  Franz, E. and Smit, L.A.M. (2023) A comprehensive sampling study on SARS-CoV-2
- Franz, E. and Smit, L.A.M. (2023) A comprehensive sampling study on SARS-CoV-2
   contamination of air and surfaces in a large meat processing plant experiencing COVID-19
- 458 clusters in June 2020. *J Occup Environ Med*. **Publish Ah**.
- Ryu, B.H., Cho, Y., Cho, O.H., Hong, S.I., Kim, S. and Lee, S. (2020) Environmental contamination of
   SARS-CoV-2 during the COVID-19 outbreak in South Korea. *Am J Infect Control.* 48, 875–879.
- Saloner, B., Parish, K., Ward, J.A., DiLaura, G. and Dolovich, S. (2020) COVID-19 Cases and Deaths in
  Federal and State Prisons. *JAMA*. 324, 602.
- Sun, Z.P., Yang, S.Y., Cai, X., Han, W.D., Hu, G.W., Qian, Y., Wang, Y.Y., Zhang, R., Xie, Y.H. and Qu, D.
  (2022) Survival of SARS-CoV-2 in artificial seawater and on the surface of inanimate materials. J *Med Virol.* 94, 3982–3987.
- Tian, D., Song, Y., Zhang, M., Pan, Y., Ge, Z., Zhang, Y., Ren, X., Wen, J., Xu, Y., Guo, H., Yang, P., Chen,
  Z. and Xu, W. (2022) Genomic, immunological, and clinical analysis of COVID-19 vaccine
  breakthrough infections in Beijing, China. *J Med Virol.* 94, 2237–2249.
- Topriceanu, C.-C., Wong, A., Moon, J.C., Hughes, A.D., Chaturvedi, N., Conti, G., Bann, D., Patalay, P.
  and Captur, G. (2021) Impact of lockdown on key workers: findings from the COVID-19 survey
  in four UK national longitudinal studies. *J Epidemiol Community Health.* **75**, 955–962.
- Warren, B.G., Nelson, A., Barrett, A., Addison, B., Graves, A., Binder, R., Gray, G., Lewis, S., Smith,
  B.A., Weber, D.J., Sickbert-Bennett, E.E. and Anderson, D.J. (2022) Severe acute respiratory
  syndrome coronavirus 2 environmental contamination in hospital rooms is uncommon using
  viral culture techniques. *Clin Infect Dis.* **75**, e307–e309.
- WHO (2020) WHO Director-General's opening remarks at the media briefing on COVID-19 11
   March 2020 [WWW Document]. URL https://www.who.int/director-

- 478 general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-
- 479 covid-19---11-march-2020.

Site	Workplace Sector	Workforce size <sup>†</sup>	Estimated attack rate <sup>‡</sup>	Sampling Performed	Time from outbreak cases to sampling
001	Manufacturing	200-300	10%	March 2021	>10 days
002	Manufacturing	200-300	14%	March 2021	Ongoing
003	Distribution	>1000	6%	May 2021	Ongoing
004	Office	100-200	12%	May 2021	>14 days
005	Food	>1000	3%	June 2021	Ongoing
007	Critical Infrastructure	100-200 (20-30)*	5% (39%)	July 2021	>14 days
008	Office	<50	55%	September 2021	Ongoing**
009	Manufacturing	<50	14%	October 2021	>21 days
010	Manufacturing	200-300	10%	November 2021	>7 days
012	Food	200-300	9%	January 2022	>14 days
013	Food	100-200	21%	February 2022	>21 days
020	Food	<50	32%	March 2022	4 days
C1	Critical Infrastructure	500-1000	Unknown	July 2021	NA
C2	Critical Infrastructure	300-400	Unknown	March 2022	NA

481 Table 1: Details of workplaces sampled for the presence of SARS-CoV-2 RNA as part of the COVID-482 OUT study. Sites 006, 011 and 014-019 did not give approval (or were not eligible) for the 483 environmental sampling component of the study. C1 = control site 1, C2 = control site 2, NA = not 484 applicable, Unknown = no outbreak reported but sporadic cases likely present in workforce. 485 <sup>†</sup>Workforce size is presented as a range as this is potentially identifiable information. <sup>‡</sup>Attack rate 486 calculated as the number of COVID cases reported in the outbreak report divided by exact workforce 487 size at that specific site (this is does distinguish between staff working on site and those who may be 488 working from home during the outbreak period). \*Outbreak confined to one cohort within the work 489 environment; data provided for both the cohort and the wider workplace. \*\*Last case reported at 490 the time of sampling; however, site was closed for nine days prior to sampling with minimal staff 491 present.

492

493

Site	Samples	Positive	Suspected	Negative	Ct ≤35.0
(Month)	collected	(%)	(%)	(%)	(%)
001 (M)	26	14	3	19	2
March 2021	30	(38.9%)	(8.3%)	(52.8%)	(5.6%)
002 (M)	66	8	11	47	0
March 2021	00	(12.1%)	(16.7%)	(71.2%)	(0.0%)
003 (D)	76	25	14	37	7
May 2021	70	(32.9%)	(18.4%)	(48.7%)	(9.2%)
004 (O)	60	2	7	60	0
May 2021	69	(2.9%)	(10.1%)	(87.0%)	(0.0%)
005 (F)	60	1	6	53	1
June 2021	00	(1.7%)	(10.0%)	(88.3%)	(1.7%)
007 (CI)	90	0	0	90	0
July 2021		(0.0%)	(0.0%)	(100.0%)	(0.0%)
008 1 <sup>st</sup> visit (O)	60	10	1	49	5
September 2021	00	(16.7%)	(1.7%)	(81.7%)	(8.3%)
008 2 <sup>nd</sup> visit (O)	12	1	1	40	0
September 2021*	42	(2.4%)	(2.4%)	(95.2%)	(0.0%)
009 (M)	70	0	1	69	0
October 2021	70	(0.0%)	(1.4%)	(98.6%)	(0.0%)
010 (M)	55	0	0	55	0
November 2021	55	(0.0%)	(0.0%)	(100.0%)	(0.0%)
012 (F)	65	0	0	65	0
January 2022	00	(0.0%)	(0.0%)	(100.0%)	(0.0%)
013 (F)	69	0	0	69	0
February 2022	03	(0.0%)	(0.0%)	(100.0%)	(0.0%)
020 (F)	71	0	1	70	0
March 2022	71	(0.0%)	(1.4%)	(98.6%)	(0.0%)
Total	020	61	45	723	15
rotai	029	(7.4%)	(5.4%)	(87.2%)	(1.8%)

494 **Table 2**: Sampling results from recruited workplaces reporting a recent outbreak of COVID-19 in

495 their workforce. Type of site indicated using the following codes: (M) Manufacturing, (D)

496 Distribution, (O) Offices, (F) Food sector industry, or (CI) Critical infrastructure. Ct = Crossing

threshold value based on average of two duplicate samples against the nucleocapsid gene.

Site	Samples collected	Positive	Suspected	Negative	Ct ≤35.0
(Month)		(%)	(%)	(%)	(%)
Control Site 1	64	0	2	62	0
July 2021		(0.0%)	(3.1%)	(96.9%)	(0.0%)
Control Site 2	72	1	2	69	0
March 2022		(1.4%)	(2.8%)	(95.8%)	(0.0%)
Total	136	1 (0.7%)	4 (2.9%)	131 (96.4%)	0 (0.0%)

Table 3: Sampling results from two critical infrastructure control sites; neither site reported a recent
 outbreak of COVID-19 within their workforce. Ct = Crossing threshold value based on average of two
 duplicate samples against the nucleocapsid gene.





**Figure 1:** Proportion of positive samples, suspected positive samples and samples returning Ct values 508 of  $\leq$  35.0 by site visited.



Figure 2: Proportion of positive samples, suspected positive samples and samples returning Ct values
of ≤35.0 from 829 surface samples collected from recruited workplace ordered by area of sampling.
Four samples, which included one suspected positive, collected from outdoor locations are not
shown for y-axis scaling purposes.





Figure 3: Proportion of positive samples, suspected positive samples and samples returning Ct values
 of ≤35.0 from 524 surface samples classed as 'high-touch' locations collected from recruited

- 521 workplace ordered by area of sampling. Four samples, which included one suspected positive,
- 522 collected from outdoor locations are not shown for y-axis scaling purposes.